Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease
| العنوان: | Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease |
|---|---|
| المؤلفون: | null Aline Floch, null Alexandre Morel, null Fabian Zanchetta-Balint, null Catherine Cordonnier-Jourdin, null Slimane Allali, null Maximilien Grall, null Ghislaine Ithier, null Benjamin Carpentier, null Sadaf Pakdaman, null Jean-Claude Merle, null Radjiv Goulabchand, null Tackwa Khalifeh, null Ana Berceanu, null Cécile Helmer, null Christelle Chantalat-Auger, null Véronique Frémeaux-Bacchi, null Marc Michel, null Mariane de Montalembert, null Armand Mekontso-Dessap, null France Pirenne, null Anoosha Habibi, null Pablo Bartolucci |
| المساهمون: | Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CIC - Biotherapie - CHU Henri Mondor, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint Vincent de Paul de Lille, Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), IMRB - 'Transfusion et Maladies du Globule Rouge' [Créteil] (U955 Inserm - UPEC), Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL) |
| المصدر: | Haematologica Haematologica, Ferrata Storti Foundation, 2020, 105 (11), pp.2694-2697. ⟨10.3324/haematol.2020.253856⟩ |
| بيانات النشر: | HAL CCSD, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, [SDV]Life Sciences [q-bio], Inflammation, Case Reports, Anemia, Sickle Cell, 030204 cardiovascular system & hematology, Hemolysis, MESH: Anemia, Sickle Cell* / therapy, MESH: Transfusion Reaction, 03 medical and health sciences, Classical complement pathway, 0302 clinical medicine, Antigen, Isoantibodies, medicine, Humans, MESH: Humans, biology, business.industry, Transfusion Reaction, Transfusion medicine, Hematology, medicine.disease, MESH: Hemolysis, MESH: Isoantibodies, 3. Good health, Delayed hemolytic transfusion reaction, Immunology, Alternative complement pathway, biology.protein, medicine.symptom, Antibody, business, Packed red blood cells, 030215 immunology |
| الوصف: | International audience; Delayed hemolytic transfusion reaction (DHTR) is an unpredictable severe complication of transfusion in patients with sickle cell disease (SCD). It presents clinically as a vaso-occlusive crisis (VOC), often associated with the failure of one or more organs, after the transfusion of packed red blood cells (pRBC).1,2 Hyperhemolysis is encountered in the most severe forms. Both transfused and autologous red blood cells (RBC) are lysed.The mechanisms underlying DHTR remain unclear. Alloantibodies against RBC antigens were initially thought to underlie the pathophysiology, but no such antibodies are detected in about a third of the cases.3RBC degradation products, such as hemoglobin and heme, are released into the bloodstream during intravascular hemolysis. These elements and heme-loaded membrane microvesicles have recently been implicated in inflammation and organ injury in DHTR.4 Complement is activated via the classical pathway, by alloantibodies, and/or via the alternative pathway, by free heme.5 Hemedependent complement deposits on the endothelium contribute to organ damage.6 Due to these vascular lesions, hyperhemolysis often progresses to multiple organ failure and, in some cases, death. |
| اللغة: | English |
| تدمد: | 0390-6078 1592-8721 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5128c1c7696ed75f2a568f41ddfbc273Test https://hal.umontpellier.fr/hal-03281666Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5128c1c7696ed75f2a568f41ddfbc273 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 03906078 15928721 |
|---|